

P24028.A01



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Chong-Oh KIM et al.

Appln. No : 10/635,615

Filed : August 7, 2003

For : RADIOACTIVE MAGNETIC FLUIDS FOR TREATMENT OR DIAGNOSIS OF  
CANCER, PROCESS FOR PREPARING THEM AND USE THEREOF

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir :

In accordance with the duty of disclosure under 37 C.F.R. §§ 1.56, 1.97, and 1.98, Applicants hereby bring the following information to the attention of the Examiner in charge of the above-identified application, which includes information cited and discussed in the specification.

U.S. Patent No. 5,921,244, which is cited and discussed in the specification beginning on page 3, line 11;

U.S. Patent No. 4,957,481, which is cited and discussed in the specification beginning on page 3, line 15;

Urs HAFELI et al., "Radiolabeling of Magnetic Particles with Rhenium-188 for Cancer Therapy", Journal of Magnetism and Magnetic Materials, Vol. 225, pp. 73-78 (2001), which is cited and discussed in the specification beginning on page 6, line 23;

P24028.A01

Ch. ALEXIOU et al., "Magnetic Drug Targeting: Biodistribution and Dependency on Magnetic Field Strength", Journal of Magnetism and Magnetic Materials, Vol. 252, pp. 363-366 (2002), which is cited and discussed in the specification beginning on page 7, line 4; and


Yuqiang HUANG et al., "Preparation of nanometric  $\text{Cu}_x\text{Fe}_{1-x}\text{OFe}_2\text{O}_3$  for Treatment of Tumor", Journal of Applied Physics, Vol. 93, No. 10, pp. 8444-8446 (2003).

Copies of the above-noted documents are enclosed together with a duly completed Form PTO-1449. The Examiner is accordingly requested to consider each of these documents, and to make them of record in this application by initialing in the appropriate spaces on the Form PTO-1449. Applicants respectfully request that the Examiner include a copy of the initialed Form PTO-1449 with the next communication from the U.S. Patent and Trademark Office.

In accordance with 37 C.F.R. § 1.97(b)(1), this Information Disclosure Statement is filed within three months of the filing date of the application. Accordingly, no fees are required.

Should there be any questions, the Examiner is invited to contact the undersigned at the below listed telephone number.

Respectfully submitted,  
Chong-Oh KIM et al.

  
Bruce H. Bernstein  
Reg. No. 29,027

*Reg. No. 33,097*

November 6, 2003  
GREENBLUM & BERNSTEIN, P.L.C.  
1950 Roland Clarke Place  
Reston, VA 20191  
(703) 716-1191



Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
P24028Serial No.  
10/635,615

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**  
(Use several sheets if necessary)

Applicants  
Chong-Oh KIM et al.Filing Date  
August 7, 2003Group  
Unknown**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5 9 2 1 2 4 4	07/13/99	CHEN et al.			
	4 9 5 7 4 8 1	09/18/90	GATENBY			

**FOREIGN PATENT DOCUMENTS**

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

1	Urs HAFELI et al., "Radiolabeling of Magnetic Particles with Rhenium-188 for Cancer Therapy", Journal of Magnetism and Magnetic Materials, Vol. 225, pp. 73-78 (2001).
2	Ch. ALEXIOU et al., "Magnetic Drug Targeting: Biodistribution and Dependency on Magnetic Field Strength", Journal of Magnetism and Magnetic Materials, Vol. 252, pp. 363-366 (2002).
3	Yuqiang HUANG et al., "Preparation of nanometric $\text{Cu}_x\text{Fe}_{1-x}\text{OFe}_2\text{O}_3$ for Treatment of Tumor", Journal of Applied Physics, Vol. 93, No. 10, pp. 8444-8446 (2003).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.